tbuckley/cabot-search huggingface dataset:
THU0449 Ultrasound-Detected Inflammation Predicts Radiographic Progression in Hand Osteoarthritis After Five Years
Authors: A. Mathiessen, H.B. Hammer, B. Slatkowsky-Christensen, T.K. Kvien, I.K. Haugen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Modern imaging techniques such as magnetic resonance imaging and ultrasound demonstrate high prevalence of synovitis in painful hand OA joints. Some studies on knee OA suggest that the presence of synovitis may be a surrogate marker of OA severity and associated with increased risk of disease progression. A similar predictive correlation is less clear for hand OA due to few longitudinal studies. <h3>Objectives</h3> To examine whether ultrasound inflammation including grey scale (GS) synovitis and power Doppler (PD) activity can predict radiographic progression after 5 years in patients with hand OA. <h3>Methods</h3> We included 78 participants (71 women, mean (SD) age 67.8 (5.2) years) from the Oslo hand OA cohort with US examination at baseline and conventional radiographs taken at baseline and 5-years follow-up. GS and PD were examined in 30 finger joints by US on a semi-quantitative 0-3 scale. Radiographic progression was defined as an increase in global OA according to the Kellgren-Lawrence (KL) scale, or progression of individual OA features according to the OARSI atlas. For each radiographic definition we examined whether baseline US features predicted radiographic progression using Generalized Estimating Equations, adjusted for age, sex, body mass index, follow-up time and KL grade. <h3>Results</h3> Mean (SD) follow-up time was 4.7 (0.4) years. GS and PD were present in 28.7 and 4.6% of OA joints at baseline, respectively. Radiographic progression in joints was found in 20.1% for KL, 12.1% for joint space narrowing (JSN) and 11.7% for osteophytes. GS and PD were significant and dose-dependent predictors for KL progression (OR=3.1 (95% CI 2.1-4.4) and OR=4.1 (95% CI 2.1-8.0), respectively). GS and PD also predicted progression of all measures of individual radiographic features (table), of which strongest association was seen for osteophyte progression (OR=2.9 (95% CI 2.1-4.0) and OR=5.1 (95% CI 2.8-9.5), respectively). <h3>Conclusions</h3> Our study is the first to demonstrate that even small amounts of inflammation seen by ultrasound significantly increase the risk of future radiographic progression in the same finger joint. GS synovitis and PD activity were significantly associated with increased KL grade, JSN, osteophyte score and erosive evolution after 5 years. This study supports the use of US as a tool to detect hand OA patients who are likely to progress. <h3>Disclosure of Interest</h3> None declared
Focal Adhesion Kinase (FAK) Is Required for CXCL12-Induced Dhemotaxis and Adhesion to VCAM-1 in B Lymphocytes and Hematopoietic Stem/Progenitor Cells.
Authors: Leslie E. Silberstein, Derek Dykxhoorn, Yi Le, Marek Honczarenko, Judy Lieberman, Aleksandra Glodek
Journal: Blood (2006)
Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.
Authors: Francisco Tripp, Enrique Báez, Elsa Ávila, Severiano Baltazar, Oscar Garcés, Gustavo Reyes, Benjamín Batista, Alva Zaragoza, Jorge Vela-Ojeda, Luis Villela
Journal: Blood (2007)
Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Wolfram Poenisch, Malvina Bourgeois, Barbara Moll, Simone Heyn, Nadja Jäkel, Robert Rohrberg, Hans Juergen Hurtz, Marion Schmalfeld, Michael Assmann, Thomas Edelmann, Martin Mohren, Franz-Albert Hoffmann, Andreas Schwarzer, Gerald Hensel, Kerstin Loeschcke, Cornelia Becker, Rainer Krahl, Ina Wagner, Haifa K. Al-Ali, Dietger Niederwieser
Journal: Blood (2012)
Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells
Authors: Jumpei Teramachi, Kyaw Ze Yar Myint, Rentian Feng, Xiangqun Xie, Jolene J. Windle, David Roodman, Noriyoshi Kurihara
Journal: Blood (2011)
Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study
Authors: Rosa Ahn, Alexandra Woodbridge, Ann Abraham, Susan Saba, Deborah Korenstein, Erin Madden, W John Boscardin, Salomeh Keyhani
Journal: BMJ (2017)

To examine the association between the presence of individual principal investigators' financial ties to the manufacturer of the study drug and the trial's outcomes after accounting for source of research funding. Cross sectional study of randomized controlled trials (RCTs). Studies published in "core clinical" journals, as identified by Medline, between 1 January 2013 and 31 December 2013. Random sample of RCTs focused on drug efficacy. Association between financial ties of principal investigators and study outcome. A total of 190 papers describing 195 studies met inclusion criteria. Financial ties between principal investigators and the pharmaceutical industry were present in 132 (67.7%) studies. Of 397 principal investigators, 231 (58%) had financial ties and 166 (42%) did not. Of all principal investigators, 156 (39%) reported advisor/consultancy payments, 81 (20%) reported speakers' fees, 81 (20%) reported unspecified financial ties, 52 (13%) reported honorariums, 52 (13%) reported employee relationships, 52 (13%) reported travel fees, 41 (10%) reported stock ownership, and 20 (5%) reported having a patent related to the study drug. The prevalence of financial ties of principal investigators was 76% (103/136) among positive studies and 49% (29/59) among negative studies. In unadjusted analyses, the presence of a financial tie was associated with a positive study outcome (odds ratio 3.23, 95% confidence interval 1.7 to 6.1). In the primary multivariate analysis, a financial tie was significantly associated with positive RCT outcome after adjustment for the study funding source (odds ratio 3.57 (1.7 to 7.7). The secondary analysis controlled for additional RCT characteristics such as study phase, sample size, country of first authors, specialty, trial registration, study design, type of analysis, comparator, and outcome measure. These characteristics did not appreciably affect the relation between financial ties and study outcomes (odds ratio 3.37, 1.4 to 7.9). Financial ties of principal investigators were independently associated with positive clinical trial results. These findings may be suggestive of bias in the evidence base.
Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).
Authors: Todd L. Rosenblat, Michael R. McDevitt, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Suzanne Chanel, Mark G. Frattini, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic
Journal: Blood (2007)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - EBMT Risk Score Evaluation for Chronic Myeloid Leukemia in Brazil.
Authors: Carmino De Souza, Afonso C. Vigorito, Milton A. Ruiz, Márcio Nucci, Frederico L. Dulley, Vaneusa M. Fincke, Daniel Tabak, Alexandre M. Azevedo, Rita Byington, Maria C.M. Macedo, Rosaura Saboya, Francisco J.P. Aranha, Gislaine B. Oliveira, Roberto Zulli, Eliana C.M. Miranda, Wellington M. Azevedo, Fernanda M. Lodi, José C. Voltarelli, Belinda P. Simões, Vergílio Colturato, Mair P. De Souza, Lúcia Silla, Henrique Bittencourt, Lilian P. Ruiz, Angelo Maiolino, Alois Gratwohl, Ricardo Pasquini
Journal: Blood (2004)
Synergic Effects of Proteasome Inhibitor PS-341 and Tyrosine Kinase Inhibitor STI571 on Chronic Myeloid Leukemia Cells and BCR-ABL Oncoprotein In Vitro and In Vivo.
Authors: Guangbiao Zhou, Zheng Hu, Dapeng Liu, Fuqun Wu, Jiang Zhu, Saijuan Chen, Xiaoli Liu, Juan Li, Xiaofeng Li, Fengxiang Zhang
Journal: Blood (2006)
Abstract 3176: Prognostic Value of Diabetes in Patients with Heart Failure According to Etiology. Data from the IN-CHF Registry
Authors: Gianna Fabbri, Mario Barbiero, Bianca Bianchini, Antonio Geri Brandinelli, Emanuele Carbonieri, Lucio Gonzini, Calogero Minneci, Aldo P Maggioni
Journal: Circulation (2006)

BACKGROUND. Diabetes (D) and ischemic etiology have been identified as independent predictors of increased mortality in patients (pts) with heart failure (HF). However, there are few data on the pr...
Delayed Infusion of Allogeneic Stem Cells (72 Hours) Does Not Reduce the Severity of Acute Graft Versus Host Disease in Patients with Chronic Myeloid Leukemia after Myeloablative Conditioning Regimen.
Authors: Jan Maciej Zaucha, Lidia Gil, Magdalena Dutka, Anna Czyz, Maria Bieniaszewska, Maria Kozlowska-Skrzypczak, Wanda Knopinska-Posluszny, Andrzej Hellmann, Mieczyslaw Komarnicki
Journal: Blood (2005)
Novel Role for Bioactive Lipids in Mobilization of Bone Marrow Stem Cells During Myocardial Ischemia: Sphingosine-1 Phosphate (S1P) As Potential Therapeutic Target
Authors: Ahmed Abdel Latif, Anush K. Karapetyan, Yuri Klyachkin, Manjula Sunkara, Susan Smyth, Mariusz Z Ratajczak, Andrew J. Morris
Journal: Blood (2012)
Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets
Authors: Louise V Wain, Nick Shrine, María Soler Artigas, A Mesut Erzurumluoglu, Boris Noyvert, Lara Bossini-Castillo, Ma'en Obeidat, Amanda P Henry, Michael A Portelli, Robert J Hall, Charlotte K Billington, Tracy L Rimington, Anthony G Fenech, Catherine John, Tineka Blake, Victoria E Jackson, Richard J Allen, Bram P Prins, Archie Campbell, David J Porteous, Marjo-Riitta Jarvelin, Matthias Wielscher, Alan L James, Jennie Hui, Nicholas J Wareham, Jing Hua Zhao, James F Wilson, Peter K Joshi, Beate Stubbe, Rajesh Rawal, Holger Schulz, Medea Imboden, Nicole M Probst-Hensch, Stefan Karrasch, Christian Gieger, Ian J Deary, Sarah E Harris, Jonathan Marten, Igor Rudan, Stefan Enroth, Ulf Gyllensten, Shona M Kerr, Ozren Polasek, Mika Kähönen, Ida Surakka, Veronique Vitart, Caroline Hayward, Terho Lehtimäki, Olli T Raitakari, David M Evans, A John Henderson, Craig E Pennell, Carol A Wang, Peter D Sly, Emily S Wan, Robert Busch, Brian D Hobbs, Augusto A Litonjua, David W Sparrow, Amund Gulsvik, Per S Bakke, James D Crapo, Terri H Beaty, Nadia N Hansel, Rasika A Mathias, Ingo Ruczinski, Kathleen C Barnes, Yohan Bossé, Philippe Joubert, Maarten van den Berge, Corry-Anke Brandsma, Peter D Paré, Don D Sin, David C Nickle, Ke Hao, Omri Gottesman, Frederick E Dewey, Shannon E Bruse, David J Carey, H Lester Kirchner, Stefan Jonsson, Gudmar Thorleifsson, Ingileif Jonsdottir, Thorarinn Gislason, Kari Stefansson, Claudia Schurmann, Girish Nadkarni, Erwin P Bottinger, Ruth J F Loos, Robin G Walters, Zhengming Chen, Iona Y Millwood, Julien Vaucher, Om P Kurmi, Liming Li, Anna L Hansell, Chris Brightling, Eleftheria Zeggini, Michael H Cho, Edwin K Silverman, Ian Sayers, Gosia Trynka, Andrew P Morris, David P Strachan, Ian P Hall, Martin D Tobin
Journal: Nature Genetics (2017)
PET-PANC: Multi-centre prospective diagnostic accuracy and clinical value trial of FDG PET/CT in the diagnosis and management of suspected pancreatic cancer.
Authors: Paula Ghaneh, Wai Lup Wong, Andrew Titman, Catrin Plumpton, Sobhan Vinjamuri, Colin Johnson, Mohammed Abu Hilal, Antony Higginson, Andrew M Smith, Andrew Scarsbrook, Colin McKay, Robert Suttcliffe, Hemant Kocher, David Cunningham, Stephen P. Pereira, Brian Davidson, David Chang, Saboor Khan, Christopher Halloran, John P. Neoptolemos
Journal: Journal of Clinical Oncology (2016)

4008 Background: Pancreatic cancer diagnosis and staging is challenging. FDG PET/CT adds anatomic localization to functional data. The aim of this study was to determine the impact of FDG PET/CT in addition to standard diagnostic workup in patients with suspected pancreatic cancer. Methods: Patients with suspected pancreatic cancer underwent FDG PET/CT following multi-detector CT (MDCT). FDG PET/CT scans were reviewed and quality assured centrally. Diagnosis, staging and planned management were recorded before and after FDG PET/CT. Reference standard was histology or clinical outcome. Primary outcome measure was incremental diagnostic value of FDG PET/CT in addition to MDCT. Sample size was 500 patients, following interim analysis; 80% power to detect increase in sensitivity from 81% to 90% and specificity from 66% to 80%. Secondary outcome measures were changes in diagnosis, staging, and management; cost effectiveness was estimated. Results: Between January 2011 and April 2013 589 patients with suspected pancreatic cancer underwent MDCT and FDG PET/CT in 18 UK centres. 550 patients had complete data and in range FDG PET/CT. 261 patients (47%) had pancreatic ductal adenocarcinoma (PDAC). For the diagnosis of PDAC, both sensitivity (92.7% [95% CI 89.6%, 95.9%] compared to 88.5% [95% CI 84.6%, 92.4%], p=0.010) and specificity (75.8% [95% CI 70.8%, 80.7%] compared to 70.6% [95% CI 65.3%, 75.8%] p=0.023) were significantly higher for FDG PET/CT than MDCT. FDG PET/CT correctly changed the staging of PDAC in 56 patients (14%) (p=0.001). FDG PET/CT influenced management in 250 (45%) of patients. FDG PET/CT stopped futile resection in 58 patients (20%) due to have surgery. FDG PET/CT was associated with a QALY gain of 0.0157 (95% CI -0.0101, 0.0430) and cost saving of £645 (95% CI -£1314, £2743). In the base case model FDG PET/CT dominated MDCT alone and is likely to be cost effective for the UK NHS. Conclusions: FDG PET/CT provided significant incremental diagnostic benefit in the diagnosis of pancreatic cancer and had a significant influence on the staging and management of patients. FDG PET/CT was cost effective at current reimbursement rates for FDG PET/CT to the UK NHS. Clinical trial information: 73852054.
What causes occupational asthma in cleaners?
Authors: Vicky C Moore, P Sherwood Burge, Alastair S Robertson, Gareth I Walters
Journal: Thorax (2017)

Epidemiological studies have consistently found cleaners to be at increased risk of new-onset asthma,1 ,2 the risk seems to be particularly high in domestic cleaners using spray bleaches.2 Due to the large numbers employed in cleaning, they constitute a significant proportion of the population attributable risk of occupational asthma. It has, however, been very difficult to identify the precise cause of domestic cleaners' asthma from specific inhalation challenge (SIC) tests. Chlorine-based substances form the basis of many domestic (sodium hypochlorite) and healthcare (sodium dichloroisocyanurate) cleaning agents. Approximately one third of workers exposed to cleaning agents notified to the UK Health and Safety Executive SWORD (surveillance of work-related and occupational respiratory disease) database with occupational asthma are reported to be due to chlorine-releasing agents (personal communication from Raymond Agius, Institute of Occupational and Environmental Health, University of Manchester). At the Birmingham Occupational Lung Disease Service UK, we have seen 12 healthcare professionals and cleaners with occupational asthma who were exposed to chlorine-releasing agents. In the four investigated with SICs, testing was negative to chlorine-releasing tablets mixed with cold water, and other agents to which they were exposed. Chloramines, particularly nitrogen trichloride, have however been shown to be the cause of asthma in swimming pool attendants and teachers where the chlorine in the water reacts with nitrogen in the urine and sweat of swimmers.3 We hypothesised that similar reactions may be responsible for the asthma in domestic cleaners and healthcare workers and therefore carried out further investigations on the fourth …
Extended Follow-Up of a Chemo-Immunotherapy Regimen FCR (Fludarabine, F; Cyclophosphamide, C; and Rituximab, R) as Initial Therapy for Chronic Lymphocytic Leukemia (CLL).
Authors: Michael J. Keating, Susan O’Brien, Maher Albitar, Susan Lerner, William Wierda, Hagop Kantarjian
Journal: Blood (2005)
Kruppel-Like Factor, Klf9, Promotes Proliferation of Notch-Independent Precursor T-Cell Lymphoblastic Lymphomas
Authors: Peggy P. C. Wong, Daniele Merico, Irina Matei, Vicki Ling, Shaheena Bashir, Stephen G. Chang, Queenie C. K. Cheung, Robin A. Haw, Oliver Stueker, Bertrand Montpellier, Gary D. Bader, Joseph Beyene, Jayne S. Danska, Cynthia J. Guidos
Journal: Blood (2012)
High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.
Authors: Barbara Scappini, Giacomo Gianfaldoni, Palmieri Salvatore, Maria Chiara Susini, Teresa Izzo, Francesco Mannelli, Giovanni Longo, Rosa Fanci, Felicetto Ferrara, Alberto Bosi
Journal: Blood (2009)
BCR/ABL Fusion Gene On Constitutional Der(14;22) Roberstsonian Translocation in a Case of Chronic Myeloid Leukemia with Masked Philadelphia Chromosome
Authors: Pablo Lopez, Daniela Infante, Isabel Moro, Victoria Elizondo, Gerardo Romanelli, Solange Simonet, M. Rosario Uriarte Escuder, Natacha Gardiol, Juan Zunino, Marina Lafage, Rossana Bonomi
Journal: Blood (2012)
Bogus doctor jailed a second time for using fake credentials
Authors: Clare Dyer
Journal: BMJ (2017)

A bogus doctor, who was jailed in 2011 after posing as a GP and working for nine years in NHS roles in south London, has been sent to prison again for using false credentials to apply for senior health jobs.

Conrad de Souza was sentenced to 17 months in prison after pleading guilty to six charges of fraud. This time he was not posing as a doctor but he admitted to lying about his previous convictions and falsifying his …
Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA
Authors: Christian T. Dietz, Alice Charlotte Fabarius, Michael Lauseker, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, Brigitte Schlegelberger, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Nicolaus Kröger, Dietrich W. Beelen, Jürgen Novotny, Christoph Nerl, Christof Scheid, Karsten Spiekermann, Jiri Mayer, Herbert G. Sayer, Christiane Falge, Donald Bunjes, Hartmut Döhner, Arnold Ganser, Peter Brossart, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, Matthias Bormann, Bernd Hertenstein, Gabriela M. Baerlocher, Carlo Aul, Peter Staib, Matthias Edinger, Michael Schatz, Axel A Fauser, Renate Arnold, Dieter K. Hossfeld, Hans-Jochem Kolb, Susanne Schnittger, Martin C. Müller, Andreas Reiter, Andreas Hochhaus, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann
Journal: Blood (2015)
Metabolomic Profiling Identifies Hypoxia-Induced Imbalanced Lands' Cycle Promotes Sickling and Disease Progression
Authors: Hongyu Wu, Mikhail Bogdanov, Yujin Zhang, Kaiqi Sun, Anren Song, Hong Liu, Morayo G, Adebiyi, Danny C. Alexander, Michael V. Milburn, Modupe Idowu, Harinder S. Juneja, Yang Xia
Journal: Blood (2015)
The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.
Authors: Derek A. West, David M. Lucas, Melanie E. Davis, Michael D. De Lay, Amy J. Johnson, Sara E. Guster, Michael A. Freitas, Mark R. Parthun, Dasheng Wang, Samuel K. Kulp, Michael R. Grever, Ching-Shih Chen, John C. Byrd
Journal: Blood (2006)
B-CLL Antibodies Encoded by Stereotypic VH1-69, D3-16, and JH3 Rearrangements Immunoprecipitate Non-Muscle Myosin Heavy Chain IIA.
Authors: Charles C. Chu, Lu Zhang, Katerina Hatzi, Rosa Catera, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2007)
Transcriptional Regulation of a Distinct GATA-1 Isoform during Selection of the Mast and Erythroid Lineages.
Authors: Clifford M. Takemoto, Amir H. Shahlaee, Ying Ye, Karen I. Zeller, Daniela Zablocki, Jimmy Huynh, Suming Huang, Rodney P. DeKoter, Anil G. Jegga, Bruce J. Aronow, Chi V. Dang, Michael A. McDevitt
Journal: Blood (2004)
Targeted Disruption of the Mouse Mitoferrin (Slc25A37) Mitochondrial Solute Carrier Results in Defective Primitive and Definitive Erythropoiesis.
Authors: Barry H. Paw, Babette Gwynn, Nathaniel B. Langer, George C. Shaw, Amy J. Lambert, Leah A. Boyer, Liangtao Li, Jens Stolte, Raymond F. Robledo, Kenneth E. Sahr, Thorsten M. Schlaeger, Matthias W. Hentze, Martina U. Muckenthaler, Jerry Kaplan, Luanne L. Peters
Journal: Blood (2006)
The Current State of NAD<sup>+</sup>‐Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets
Authors: Matthias Schiedel, Dina Robaa, Tobias Rumpf, Wolfgang Sippl, Manfred Jung
Journal: Medicinal Research Reviews (2017)

Abstract Sirtuins are NAD + ‐dependent protein deacylases that cleave off acetyl, as well as other acyl groups, from the ε‐amino group of lysines in histones and other substrate proteins. Seven sirtuin isotypes (Sirt1–7) have been identified in mammalian cells. As sirtuins are involved in the regulation of various physiological processes such as cell survival, cell cycle progression, apoptosis, DNA repair, cell metabolism, and caloric restriction, a dysregulation of their enzymatic activity has been associated with the pathogenesis of neoplastic, metabolic, infectious, and neurodegenerative diseases. Thus, sirtuins are promising targets for pharmaceutical intervention. Growing interest in a modulation of sirtuin activity has prompted the discovery of several small molecules, able to inhibit or activate certain sirtuin isotypes. Herein, we give an update to our previous review on the topic in this journal (Schemies, 2010), focusing on recent developments in sirtuin biology, sirtuin modulators, and their potential as novel therapeutic agents.
The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
Authors: Mahul B. Amin, Frederick L. Greene, Stephen B. Edge, Carolyn C. Compton, Jeffrey E. Gershenwald, Robert K. Brookland, Laura Meyer, Donna M. Gress, David R. Byrd, David P. Winchester
Journal: CA A Cancer Journal for Clinicians (2017)

The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a "population-based" to a more "personalized" approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as "what's new" in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93-99. © 2017 American Cancer Society.
Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.
Authors: Paolo Lunghi, Laura Mazzera, Antonio Costanzo, Nicola Giuliani, Vittorio Rizzoli, Massimo Levrero, Antonio Bonati
Journal: Blood (2009)